SpringWorks Therapeutics, Inc. is a biopharmaceutical company that focuses on developing life-changing medicines for individuals with severe rare diseases and cancer using a precision medicine approach. With a diversified targeted oncology pipeline, the company is conducting clinical trials in rare tumor types and genetically defined cancers. Their FDA-approved therapy, OGSIVEO®, is used to treat adult patients with desmoid tumors.

Founded in 2017, SpringWorks Therapeutics has rapidly progressed their lead product candidates into late-stage trials and has established collaborations with industry innovators and academia. This strategic approach, combined with operational excellence, has allowed them to create more solutions for cancer patients and unlock the full potential of their portfolio.

On May 14th, 2024, SpringWorks Therapeutics’ management will participate in a fireside chat at the BofA Securities 2024 Health Care Conference in Las Vegas. The webcast of the chat can be accessed on the company’s website and a replay will be available for a limited time after the event. For more information about SpringWorks Therapeutics or to schedule an interview with their management team, contact Kim Diamond, Vice President of Communications and Investor Relations or Samantha Hilson Sandler, Senior Director of Investor Relations.